|Chemical and physical data|
|Molar mass||472.532 g/mol g·mol−1|
|3D model (JSmol)|
Naltalimide (INN) (code name TRK-130, formerly TAK 363) is a novel, centrally-acting opioid drug which is under development by Takeda and Toray for the treatment of overactive bladder/urinary incontinence. It acts as a potent and selective partial agonist of the μ-opioid receptor (Ki = 0.268 nM, EC50 = 2.39 nM, Emax = 66.1%) over the δ-opioid (Ki = 121 nM, EC50 = 26.1 nM, Emax = 71.0%) and κ-opioid receptors (Ki = 8.97 nM, EC50 = 9.51 nM, Emax = 62.6%). Notably, naltalimide somehow appears to lack certain undesirable side effects such as constipation seen with other μ-opioid receptor agonists such as morphine. It enhances bladder storage via suppression of the afferent limb of the micturition reflex pathway.
- Fujimura, M.; Izumimoto, N.; Momen, S.; Yoshikawa, S.; Kobayashi, R.; Kanie, S.; Hirakata, M.; Komagata, T.; Okanishi, S.; Hashimoto, T.; Yoshimura, N.; Kawai, K. (2014). “Characteristics of TRK-130 (Naltalimide), a Novel Opioid Ligand, as a New Therapeutic Agent for Overactive Bladder”. Journal of Pharmacology and Experimental Therapeutics. 350 (3): 543–551. doi:10.1124/jpet.114.214031. ISSN 1521-0103.